Back to Products

Renolina

Linagliptin

Indications:

 

Renolina is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults.

  • As monotherapy: in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance or contraindicated due to renal impairment.
  • As combination therapy: in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

 

Dosage & Administration:

 

Linagliptin 5 mg once daily. If added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly. When used in combination with a sulfonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.

Patients with renal impairment: No dose adjustment required. Linagliptin can be taken with or without a meal at any time of the day.

 

How supplied:

 

Renolina Tablet (21’s):  Each box contains 21 tablets (3 X 7’s) in Alu-Alu blister pack.